Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes
Top Cited Papers
Open Access
- 15 January 2008
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 46 (2) , 201-211
- https://doi.org/10.1086/524669
Abstract
Background. Voriconazole is the therapy of choice for aspergillosis and a new treatment option for candidiasis. Liver disease, age, genetic polymorphKeywords
This publication has 32 references indexed in Scilit:
- Altered Pharmacokinetics of Voriconazole in a Patient with Liver CirrhosisAntimicrobial Agents and Chemotherapy, 2007
- Voriconazole Therapeutic Drug MonitoringAntimicrobial Agents and Chemotherapy, 2006
- Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infectionsJournal of Antimicrobial Chemotherapy, 2006
- Improved outcome in central nervous system aspergillosis, using voriconazole treatmentBlood, 2005
- Plasma levels of voriconazole administered via a nasogastric tube to critically ill patientsEuropean Journal of Clinical Microbiology & Infectious Diseases, 2005
- Guidelines for Treatment of CandidiasisClinical Infectious Diseases, 2004
- In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis ModelAntimicrobial Agents and Chemotherapy, 2003
- Safety of Voriconazole and Dose IndividualizationClinical Infectious Diseases, 2003
- The Safety of VoriconazoleClinical Infectious Diseases, 2002
- Efficacy and Safety of Voriconazole in the Treatment of Acute Invasive AspergillosisClinical Infectious Diseases, 2002